Needham increased the company’s target price in SI-Bone (SIBN) to $20 from $19 and maintains a buy rating on the stock as part of a broader research note on the MedTech/Diagnostics sector. Following recent upfront announcements and management comments, the company is updating its forecasts on select names while advancing its valuation framework to 2026 estimates, the analyst tells investors in a research note.
First published in The Fly – The ultimate source of real-time, breaking financial news that moves the market. Try now >>
Check out popular Insiders stocks on TipRanks >>
Read more about SIBN: